The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
The company reported lifetime high EBIDTA of Rs. 250 crores
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
The product is expected to be launched in June 2023
Product deliveries scheduled in Q3 of 2023
8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector
Testing supporting allergy diagnosis now accessible to more people in more communities
These initiatives aim to improve access to healthcare for rare disease patients
Subscribe To Our Newsletter & Stay Updated
